Voyager Therapeutics (NASDAQ:VYGR) Stock Crosses Below 50 Day Moving Average – What’s Next?

Voyager Therapeutics, Inc. (NASDAQ:VYGR)’s share price passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $4.62 and traded as low as $3.85. Voyager Therapeutics shares last traded at $3.91, with a volume of 214,629 shares trading hands.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on VYGR shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Wedbush restated an “outperform” rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research note on Thursday, March 13th. Finally, Citigroup began coverage on shares of Voyager Therapeutics in a report on Monday, December 2nd. They set a “buy” rating and a $12.00 target price for the company. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Voyager Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $14.86.

Voyager Therapeutics Stock Down 2.2 %

The business’s 50-day simple moving average is $4.56 and its two-hundred day simple moving average is $5.68. The firm has a market cap of $200.95 million, a price-to-earnings ratio of 5.13 and a beta of 0.99.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.24). The business had revenue of $4.39 million during the quarter, compared to analyst estimates of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period in the previous year, the business posted $1.25 earnings per share. On average, analysts expect that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Institutional Investors Weigh In On Voyager Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP raised its position in shares of Voyager Therapeutics by 13.9% during the 4th quarter. Wellington Management Group LLP now owns 261,251 shares of the company’s stock worth $1,481,000 after purchasing an additional 31,882 shares during the last quarter. Vestal Point Capital LP lifted its position in shares of Voyager Therapeutics by 151.0% in the fourth quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company’s stock valued at $6,974,000 after acquiring an additional 740,000 shares in the last quarter. Virtus Investment Advisers Inc. increased its position in shares of Voyager Therapeutics by 59.0% during the fourth quarter. Virtus Investment Advisers Inc. now owns 20,105 shares of the company’s stock worth $114,000 after purchasing an additional 7,457 shares in the last quarter. Tema Etfs LLC acquired a new position in Voyager Therapeutics in the 4th quarter valued at $85,000. Finally, Man Group plc acquired a new position in Voyager Therapeutics in the 4th quarter valued at $234,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.